| __timestamp | Bristol-Myers Squibb Company | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 4534000000 | 15411924 |
| Thursday, January 1, 2015 | 5920000000 | 22593274 |
| Friday, January 1, 2016 | 4940000000 | 33173050 |
| Sunday, January 1, 2017 | 6411000000 | 62224159 |
| Monday, January 1, 2018 | 6345000000 | 95607434 |
| Tuesday, January 1, 2019 | 6148000000 | 221269028 |
| Wednesday, January 1, 2020 | 11143000000 | 400745069 |
| Friday, January 1, 2021 | 10195000000 | 580520000 |
| Saturday, January 1, 2022 | 9509000000 | 663366000 |
| Sunday, January 1, 2023 | 9299000000 | 755113687 |
| Monday, January 1, 2024 | 11159000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Bristol-Myers Squibb Company has consistently outpaced argenx SE in R&D investment. From 2014 to 2023, Bristol-Myers Squibb's R&D expenses surged by over 100%, peaking in 2020 with a remarkable 11 billion dollars. In contrast, argenx SE, a rising star in the biotech sector, increased its R&D spending by nearly 50 times, reaching approximately 755 million dollars in 2023. This growth trajectory highlights argenx SE's aggressive push towards innovation, albeit from a smaller base. The data underscores the contrasting strategies of a pharmaceutical giant and an emerging biotech firm, each navigating the complex landscape of drug development and innovation.
R&D Insights: How Merck & Co., Inc. and argenx SE Allocate Funds
Research and Development: Comparing Key Metrics for Novartis AG and argenx SE
R&D Spending Showdown: Pfizer Inc. vs Bristol-Myers Squibb Company
Amgen Inc. vs argenx SE: Strategic Focus on R&D Spending
R&D Insights: How Bristol-Myers Squibb Company and Halozyme Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Bristol-Myers Squibb Company vs Apellis Pharmaceuticals, Inc.
Comparing Innovation Spending: Bristol-Myers Squibb Company and Viking Therapeutics, Inc.
R&D Spending Showdown: Bristol-Myers Squibb Company vs MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and argenx SE
Research and Development: Comparing Key Metrics for argenx SE and Vericel Corporation
argenx SE vs HUTCHMED (China) Limited: Strategic Focus on R&D Spending
R&D Insights: How argenx SE and Novavax, Inc. Allocate Funds